Open Access Open Access  Restricted Access Subscription Access

Recent Advances in the Pathophysiology, Diagnosis and Therapeutic Management of Glucoma: A Comprehensive Review

Pravind Kumar Ray, Sakshi Tyagi

Abstract


Glaucoma is one of the leading causes of irreversible blindness worldwide. The disease is commonly associated with elevated intraocular pressure [IOP], although optic nerve damage can occur even at normal pressure levels. Glaucoma encompasses a heterogeneous group of disorders, including primary open-angle glaucoma, angle-closure glaucoma, congenital glaucoma, and secondary glaucomas caused by trauma, medications, or systemic diseases. Recent developments in the understanding of ocular physiology, genetics, and neurodegeneration have shown new insights into the pathophysiology of glaucoma. Dysregulation of aqueous humour dynamics, oxidative stress, mitochondrial dysfunction, neuroinflammation, and impaired ocular blood flow contribute to optic nerve damage.
Early diagnosis using advanced imaging techniques such as optical coherence tomography [OCT], tonometry, and visual field analysis is critical for preventing disease progression.
Current management strategies focus on reducing intraocular pressure through pharmacological therapy, laser treatment, and surgical interventions. Emerging therapies, including neuroprotective agents, gene therapy, stem cell therapy, and sustained drug-delivery systems, are under investigation for improved disease control. This review summarises recent developments in the epidemiology, pathophysiology, classification, diagnostic strategies, and therapeutic management of glaucoma, highlighting current challenges and future research directions in glaucoma treatment.


Full Text:

PDF

References


Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma. Nat Rev Dis Primers. 2016;2:16067.

Quigley HA. Glaucoma. Lancet. 2011;377[9774]:1367-1377.

Tham YC, Li X, Wong TY, Quigley HA, Aung T, Cheng CY. Global prevalence of glaucoma and projections of glaucoma burden through 2040. Ophthalmology. 2014;121[11]:2081-2090.

Jonas JB, Aung T, Bourne RR, Bron AM, Ritch R, Panda-Jonas S. Glaucoma. Lancet. 2017;390[10108]:2183-2193.

Kanski JJ, Bowling B. Clinical Ophthalmology: A Systematic Approach. 8th ed. Elsevier; 2019.

Wiggs JL. The genetics of glaucoma: current status and future directions. Nat Rev Genet. 2015;16[6]:343-355.

Tezel G. Immune regulation toward immunomodulation for neuroprotection in glaucoma. Prog Retin Eye Res. 2018;67:1-18.

Burgoyne CF. A biomechanical paradigm for axonal insult within the optic nerve head in aging and glaucoma. Exp Eye Res. 2011;93[2]:120-132.

Almasieh M, Levin LA. Neuroprotection in glaucoma: animal models and clinical trials. Annu Rev Vis Sci. 2017;3:91-120.

Izzotti A, Bagnis A, SaccĂ  SC. The role of oxidative stress in glaucoma. Mutat Res. 2006;612[2]:105-114.


Refbacks

  • There are currently no refbacks.